Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
June 24, 2024 12:28 PM EDTMorgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $250.00 (from $164.00) while maintaining a Equalweight rating.
The analyst comments "Top-line HELIOS-B results better-than-expected, supporting sNDA filing in late 2024. We expect focus to now shift to presentation of... More
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
June 24, 2024 11:38 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $235.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "The News: Highly anticipated HELIOS-B hits the primary endpoint (composite of all-cause mortality and recurrent CV events) in both ITT (HR 0.718, p-value 0.0118; n=654) and monotherapy (HR... More
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
June 24, 2024 7:28 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "We believe topline HELIOS-B data are highly positive and support vutrisiran becoming a blockbuster in TTR-cardiomyopathy. Specifically the trial met all... More
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
June 24, 2024 7:11 AM EDTAlnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 a.m.
